DISPATCH KILLED — OUT OF SCOPE

Analysis: The tweet volume for 2026-06-24 to 2026-06-26 within the biotech-AI intersection is critically thin.

Of the ~100 recent tweets from tracked sources:

@crypto_condom: 44 tweets on $BB (cybersecurity/robotics comms), BTC shorts, and NVIDIA partnerships — zero biotech-AI content.
@biotech2k1: 45 tweets spanning fintech, SaaS, Asia equities, and non-AI biotech ($GRAB, $KC, $PONY, $ZS, $INSM) — only 1 mentions $INSM (a brief link with no AI thesis articulation).
@maverickny: 6 tweets; 2 tangentially touch ADC data integrity concerns — marginal to the biotech-AI scope.
@adamfeuerstein: 4 tweets on $ABVX sentiment and $OCUL/$EYPT comparisons — not AI-biotech focused.
@biologyaidaily: ~7 tweets on AI protein-design papers (AbAffinity, TCRBinder, ComplexDesign, DeepSpot-M) — pure ML/comp-bio, not tied to commercial biotech-AI players or investment signals.

Why this kills the dispatch:

1. No new material on core $IOVA thesis or TIL competitors beyond what was sent 6/25 and 6/24. 2. $INSM cited once, without conviction or context—no fresh data, catalyst, or positioning. 3. Zero mentions of $BBIO, $MIRM, or other bubble biotechs that were flagged for exit risk in prior dispatches. 4. @biologyaidaily papers are academic; no implied equity positioning or company-level signals. 5. All top-engagement tweets ($BB, $BTC, fintech, Asia) are outside scope.

Conclusion: Padding this dispatch with off-scope material ($BB robotics, fintech, crypto) or stale $IOVA re-hashing would violate both the scope filter and the reader's time.

Recommendation: Hold fire and wait for material within the biotech-AI intersection with actionable conviction. The prior two dispatches (6/25, 6/24) remain current and defensible.

Biotech + AI Investors — Jun 26

DISPATCH KILLED — OUT OF SCOPE